MIRA Pharmaceuticals reported a net loss of $1.7 million for Q2 2024, with research and development expenses reaching $0.6 million primarily for Ketamir pre-clinical research projects. General and administrative expenses remained stable at $1.1 million, while the company maintained a cash position of $2.8 million as of June 30, 2024.The company's development pipeline focuses on two key neuroscience programs - Ketamir-2, a novel oral ketamine analog targeting treatment-resistant depression, and MIRA-55, an oral pharmaceutical marijuana molecule being studied for neuropathic pain and cognitive disorders. Both compounds have received favorable DEA reviews confirming they would not be classified as controlled substances.Management expects current cash reserves to fund operations through Q4 2024, though additional financing will be required for continued development. The company has implemented enhanced internal controls and filed a shelf registration statement on Form S-3 with the SEC on August 12, 2024, to provide future financing flexibility. However, substantial doubt exists about the company's ability to continue as a going concern beyond 12 months.

MIRA Pharmaceuticals reported a net loss of $1.7 million for Q2 2024, with research and development expenses reaching $0.6 million primarily for Ketamir pre-clinical research projects. General and administrative expenses remained stable at $1.1 million, while the company maintained a cash position of $2.8 million as of June 30, 2024.The company's development pipeline focuses on two key neuroscience programs - Ketamir-2, a novel oral ketamine analog targeting treatment-resistant depression, and MIRA-55, an oral pharmaceutical marijuana molecule being studied for neuropathic pain and cognitive disorders. Both compounds have received favorable DEA reviews confirming they would not be classified as controlled substances.Management expects current cash reserves to fund operations through Q4 2024, though additional financing will be required for continued development. The company has implemented enhanced internal controls and filed a shelf registration statement on Form S-3 with the SEC on August 12, 2024, to provide future financing flexibility. However, substantial doubt exists about the company's ability to continue as a going concern beyond 12 months.